Debt Extinguishment Drives Q2 Profit for Gossamer Bio; NDA Submission on Track for September
GOSS sits 54% above its 52-week low of $0.114.
Summary
Gossamer Bio reported Q2 2026 net income of $16.9 million, driven by debt extinguishment gains, and confirmed its NDA submission for seralutinib remains on track for September 2026.
Key Events · Earnings and Guidance · GOSS
-
Q2 Net Income of $16.9M
Net income for Q2 2026 reached $16.9 million, a sharp turnaround from the $38.3 million net loss in Q2 2025, driven by a $43.8 million gain on debt extinguishment and $5.7 million in non-cash warrant/derivative remeasurement gains.
-
FDA Meeting Minutes Support NDA Filing
The FDA characterized the degree of statistical significance and magnitude of treatment effect in PROSERA as review issues rather than filing issues, keeping the NDA submission for seralutinib in PAH on track for September 2026.
-
Cash Runway into Q1 2027
Cash, cash equivalents, and marketable securities totaled $57.0 million as of June 30, 2026, expected to fund operations into the first quarter of 2027.
-
Chiesi Termination Terms Disclosed
Chiesi made a one-time $5 million payment to Gossamer and is entitled to a capped royalty on worldwide net sales plus milestone payments, while Gossamer retains the substantial majority of seralutinib's global economics.
Analysis · GOSS · Life Sciences
A $43.8 million gain on debt extinguishment and non-cash warrant remeasurement gains swung Gossamer Bio to a Q2 net income of $16.9 million, reversing a $38.3 million loss from the prior year. The company also disclosed that FDA meeting minutes characterized the PROSERA trial's statistical significance as a review issue rather than a filing issue, keeping the September NDA submission on track. With cash of $57 million funding operations only into Q1 2027, the upcoming NDA and potential approval are critical.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 989 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GOSS was trading at $0.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $83.3M. The 52-week trading range was $0.11 to $3.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.